keyword
MENU ▼
Read by QxMD icon Read
search

Varenicline

keyword
https://www.readbyqxmd.com/read/29455292/effects-of-the-nicotinic-agonist-varenicline-nicotinic-antagonist-r-bpidi-and-dat-inhibitor-r-modafinil-on-co-use-of-ethanol-and-nicotine-in-female-p-rats
#1
Sarah E Maggio, Meredith A Saunders, Thomas A Baxter, Kimberly Nixon, Mark A Prendergast, Guangrong Zheng, Peter Crooks, Linda P Dwoskin, Rachel D Slack, Amy H Newman, Richard L Bell, Michael T Bardo
RATIONALE: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. OBJECTIVES: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs...
February 18, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29438157/effects-of-varenicline-alone-and-in-combination-with-low-dose-naltrexone-on-alcohol-primed-smoking-in-heavy-drinking-tobacco-users-a-preliminary-laboratory-study
#2
Walter Roberts, Julia M Shi, Jeanette M Tetrault, Sherry A McKee
OBJECTIVES: Heavy-drinking tobacco users are less likely to successfully quit smoking than their moderate-drinking counterparts, even when they are prescribed smoking cessation medication. One strategy for improving treatment outcomes in this subgroup of tobacco users may be to combine medication therapies to target both alcohol and tobacco use simultaneously. Adding naltrexone to frontline smoking cessation treatments may improve treatment outcomes in this group. METHOD: This double-blind, placebo-controlled human laboratory study examined the effects of varenicline (2 mg/d) and varenicline (2 mg/d), combined with a low dose of naltrexone (25 mg/d) on alcohol-primed smoking behavior in a laboratory model of smoking relapse in heavy-drinking tobacco users (n = 30)...
February 12, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29436984/effectiveness-of-pharmacological-or-psychological-interventions-for-smoking-cessation-in-smokers-with-major-depression-or-depressive-symptoms-a-systematic-review-of-the-literature
#3
Giulia A Aldi, Giuly Bertoli, Francesca Ferraro, Aldo Pezzuto, Fiammetta Cosci
BACKGROUND: Smokers with major depressive disorder (MDD) or depressive symptoms (DS) represent a subgroup in need of attention since they have specific clinical features and prognosis. METHODS: A systematic review of the literature (Cochrane, MEDLINE, ScienceDirect, Web Of Science databases from inception to June 2017) of randomized clinical trials assessing the effectiveness of pharmacological, psychological or combined interventions for smoking cessation in subjects with current or past MDD/DS without medical or comorbid psychiatric disorder(s) was run following the PRISMA guidelines...
February 13, 2018: Substance Abuse
https://www.readbyqxmd.com/read/29427108/clinical-features-of-machado-joseph-disease
#4
Nuno Mendonça, Marcondes C França, António Freire Gonçalves, Cristina Januário
Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and premature death. Although rare, it is the most common autosomal dominant spinocerebellar ataxia worldwide and has a distinct geographic distribution, reaching peak prevalence in certain regions of Brazil, Portugal and China. Due to its clinical heterogeneity, it was initially described as several different entities and as had many designations over the last decades...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29424192/varenicline-in-smokers-with-severe-or-very-severe-copd-after-24-weeks-of-treatment-a-descriptive-analysis-value-study
#5
Carlos A Jiménez-Ruiz, Marcos Garcia Rueda, Manuel A Martinez Muñiz, Jacobo Sellarés, Maria A Jiménez-Fuentes, Lourdes Lázaro Asegurado, Esther Rodríguez Gonzalez, Concepción Rodriguez Garcia, Oriol Armengol, Emilia Abad, Teresa Peña, Adolfo Domenech Del Rio, Juan A Riesco Miranda
A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. Little information is available about this issue.  The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24.  This study was a post-authorization, open label, observational study of prospective follow-up...
December 19, 2017: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
https://www.readbyqxmd.com/read/29405516/assessment-of-risk-evaluation-and-mitigation-strategies-rems-for-varenicline-chantix-a-multistage-patient-survey
#6
Kandace L Amend, Muhammad Younus, Kenneth R Petronis, Jingping Mo, John D Seeger, Robert Gately, Xiangmei Gu, Cheryl Enger
PURPOSE: To evaluate the Risk Evaluation and Mitigation Strategies (REMS) for varenicline by assessing patients' understanding of the varenicline medication guide (MG) at pre-specified time points: 18 months, 3 years, and 7 years after the REMS approval. METHODS: Self-administered surveys were mailed to people who received varenicline based on a pharmacy dispensing. Survey questions assessed understanding of potential risks outlined in the MG: neuropsychiatric symptoms, skin reactions, allergic reactions, and cardiovascular risks...
February 6, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29403297/a-cost-effectiveness-analysis-of-varenicline-for-smoking-cessation-using-data-from-the-eagles-trial
#7
Christine L Baker, Guilhem Pietri
Background: The cost-effectiveness of varenicline has been demonstrated in the US health care setting using the Benefits of Smoking Cessation on Outcomes (BENESCO) model to simulate the lifetime direct costs and consequences of a hypothetical cohort of US adult smokers who make a single attempt to quit. The aim of this study was to undertake an updated cost-effectiveness analysis, using current epidemiology inputs and recently published smoking cessation data from the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), the largest clinical trial of smoking cessation pharmacotherapies conducted to date...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29389170/effects-of-varenicline-on-cognitive-performance-in-heavy-drinkers-dose-response-effects-and-associations-with-drinking-outcomes
#8
Walter Roberts, Sherry A McKee
Varenicline reduces drinking in people with alcohol use disorder, but little is known about the mechanisms underlying this effect. Varenicline targets α4β2 and α7 nicotinic acetylcholine receptors, which are associated with several cognitive functions such as working memory. Varenicline may improve drinking outcomes by enhancing cognitive functioning. The current manuscript reports on cognitive outcomes from a placebo-controlled, double-blind human laboratory experiment examining the effects of varenicline on drinking behavior (Verplaetse et al...
February 2018: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29383494/two-step-progression-of-varenicline-induced-autoimmune-hepatitis
#9
Mitsuru Sakakibara, Kazuyoshi Ohkawa, Takatoshi Nawa, Yutaro Abe, Akira Kusakabe, Toshihiro Imai, Kazuhiro Katayama
We describe a rare case of drug-induced hepatitis due to the smoking cessation agent varenicline in a 46-year-old Asian woman. The liver injury progressed in two steps. First, the liver injury started in the absence of viral/autoimmune responses, and withdrawal of varenicline lowered the increase in the levels of liver enzymes immediately. Such findings suggested varenicline-induced liver injury. Second, hepatitis recurred in association with conversion of antinuclear antibody from negative to positive about 8 weeks after the initial episode...
January 30, 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29383396/differential-effects-of-%C3%AE-4%C3%AE-2-nicotinic-receptor-antagonists-and-partial-agonists-on-contextual-fear-extinction-in-male-c57bl-6-mice
#10
Munir Gunes Kutlu, Jessica M Tumolo, Courtney Cann, Thomas J Gould
RATIONALE: Numerous studies have attributed the psychopathology of post-traumatic stress disorder (PTSD) to maladaptive behavioral responses such as an inability to extinguish fear. While exposure therapies are mostly effective in treating these disorders by enhancing extinction learning, relapse of PTSD symptoms is common. Although several studies indicated a role for cholinergic transmission and nicotinic acetylcholine receptors (nAChRs) in anxiety and stress disorder symptomatology, very little is known about the specific contribution of nAChRs to fear extinction OBJECTIVES: In the present study, we examined the effects of inhibition and desensitization of α4β2 nAChRs via a full antagonist (Dihydro-beta-erythroidine (DhβE)) and two α4β2 nAChR partial-agonists (varenicline and sazetidine-A) on contextual fear extinction, locomotor activity, and spontaneous recovery of contextual fear in mice...
January 30, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29377409/diminishing-benefit-of-smoking-cessation-medications-during-the-first-year-a-meta-analysis-of-randomized-controlled-trials
#11
REVIEW
Laura J Rosen, Tal Galili, Jeffrey Kott, Mark Goodman, Laurence S Freedman
BACKGROUND AND AIMS: Although smoking cessation medications have shown effectiveness in increasing abstinence in randomized controlled trials (RCTs), it is unclear to what extent benefits persist over time. This paper assesses whether the benefits of smoking cessation medications decline over the first year. METHODS: We selected studies from three systematic reviews published by the Cochrane Collaboration. RCTs of first-line smoking cessation medications, with 6- and 12-month follow-up, were eligible for inclusion...
January 29, 2018: Addiction
https://www.readbyqxmd.com/read/29376747/estimating-the-public-economic-consequences-of-introducing-varenicline-smoking-cessation-therapy-in-south-korea-using-a-fiscal-analytic-framework
#12
Mark P Connolly, Christine L Baker, Nikolaos Kotsopoulos
BACKGROUND AND AIMS: Smoking gives rise to many cross-sectorial public costs and benefits for government. Costs arise from increased healthcare spending and work-related social benefits, while smoking itself provides significant revenue for government from tobacco taxes. To better understand the public economic impact of smoking and smoking cessation therapies, we developed a government perspective framework for assessing smoking-attributable morbidity and mortality and associated public costs...
January 29, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29363353/varenicline-induced-panic-disorder-in-a-previously-healthy-patient
#13
Shawn Nomani, Karl Torbicki, Tamara Mihic
No abstract text is available yet for this article.
January 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29329763/efficacy-and-safety-of-varenicline-for-smoking-cessation-in-people-living-with-hiv-in-france-anrs-144-inter-activ-a-randomised-controlled-phase-3-clinical-trial
#14
Patrick Mercié, Julie Arsandaux, Christine Katlama, Samuel Ferret, Aurélie Beuscart, Christian Spadone, Claudine Duvivier, Jacques Reynes, Nathalie Wirth, Laetitia Moinot, Antoine Bénard, David Zucman, Xavier Duval, Jean-Michel Molina, Bruno Spire, Catherine Fagard, Geneviève Chêne
BACKGROUND: Tobacco smoking is common in people living with HIV, but high-quality evidence on interventions for smoking cessation is not available in this population. We aimed to assess the efficacy and safety of varenicline with counselling to aid smoking cessation in people living with HIV. METHODS: The ANRS 144 Inter-ACTIV randomised, parallel, double-blind, multicentre, placebo-controlled phase 3 trial was done at 30 clinical hospital sites in France. People living with HIV who had smoked at least ten cigarettes per day for 1 year or longer, were motivated to stop smoking, were not dependent on another psychoactive substance, and had no history of depression or suicide attempt were eligible...
January 9, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29324248/varenicline-for-tobacco-dependence-treatment-in-alcohol-dependent-smokers-a-randomized-controlled-trial
#15
Ryan T Hurt, Jon O Ebbert, Ivana T Croghan, Darrell R Schroeder, Richard D Hurt, J Taylor Hays
BACKGROUND: Tobacco use is prevalent among persons with alcohol abuse and dependence. Varenicline has been shown to be the most effective pharmacotherapy for smoking cessation and may decrease alcohol consumption. The purpose of this study was to evaluate the efficacy of 12 weeks of varenicline for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. METHODS: Participants were eligible for enrollment if they were 18 years or older, smoked 10 or more cigarettes per day for at least 6 months, had current alcohol abuse or dependence, and were interested in quitting smoking...
March 1, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29320670/diagnosing-copd-and-supporting-smoking-cessation-in-general-practice-evidence-practice-gaps
#16
Jenifer Liang, Michael J Abramson, Nicholas A Zwar, Grant M Russell, Anne E Holland, Billie Bonevski, Ajay Mahal, Kirsten Phillips, Paula Eustace, Eldho Paul, Sally Wilson, Johnson George
OBJECTIVES: To review the accuracy of diagnoses of chronic obstructive pulmonary disease (COPD) in primary care in Australia, and to describe smokers' experiences with and preferences for smoking cessation. DESIGN, SETTING AND PARTICIPANTS: Patients were invited to participate if they were at least 40 years old and had visited participating general practice clinics in Melbourne at least twice during the previous 12 months, reported being current or ex-smokers with a smoking history of at least 10 pack-years, or were being managed for COPD...
January 15, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29313652/lung-cancer-smoking-cessation
#17
Kelly M Latimer
Smoking cessation for patients who smoke should be a top priority for physicians. Nicotine dependence should be considered a chronic disease, with the expectation that relapse is normal. The US Preventive Services Task Force (USPSTF) recommends that physicians screen all adults for tobacco use, advise them to stop using tobacco, and provide behavioral interventions and Food and Drug Administration-approved pharmacotherapy for cessation to adults who use tobacco. It also recommends use of the 5 As (ie, Ask, Advise, Assess, Assist, Arrange) in discussing tobacco use with patients...
January 2018: FP Essentials
https://www.readbyqxmd.com/read/29312710/effect-of-telling-patients-their-spirometric-lung-age-on-smoking-cessation-in-japanese-smokers
#18
Haruhi Takagi, Yoshiteru Morio, Toshiji Ishiwata, Kazunori Shimada, Atsumi Kume, Kayo Miura, Eriko Kuwasaki, Miharu Kato, Kuniaki Seyama, Kazuhisa Takahashi
Background: Cigarette smoking remains a significant public health problem. However, current treatment programs have not yet succeeded in sufficiently reducing smoking rates. The study aimed to examine whether patients' recognition of "spirometric-lung-age (SLA)" estimated from spirometry data prompts smoking cessation. Methods: From December 2010 to September 2011, participating smokers were prospectively enrolled into the standardized smoking cessation program (Visits 1-5 for 12 weeks) and assigned single-blindly to either SLA assessment or control groups...
December 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29281040/effectiveness-of-pharmaceutical-smoking-cessation-aids-in-a-nationally-representative-cohort-of-american-smokers
#19
Eric C Leas, John P Pierce, Tarik Benmarhnia, Martha M White, Madison L Noble, Dennis R Trinidad, David R Strong
Background: Despite strong efficacy in randomized trials, the population effectiveness of pharmaceutical aids in long-term smoking cessation is lacking, possibly because of confounding (factors that are associated with both pharmaceutical aid use and difficulty quitting). Matching techniques in longitudinal studies can remove this confounding bias. Methods: Using the nationally representative Tobacco Use Supplement to the Current Population Survey (TUS-CPS), we assessed the effectiveness of medications to aid quitting among baseline adult smokers who attempted to quit prior to one year of follow-up in two longitudinal studies: 2002-2003 and 2010-2011...
December 21, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29275967/effectiveness-and-safety-of-varenicline-and-nicotine-replacement-therapy-among-mental-health-patients-a-retrospective-cohort-study
#20
C A Jimenez-Ruiz, J F Pascual-Lledó, A Cícero-Guerrero, M Cristóbal-Fernández, M Mayayo-Ulibarri, C Villar-Laguna
OBJECTIVE: To analyse the effectiveness and safety of two smoking cessation medications (varenicline and nicotine patches) in patients with controlled psychiatric disorders in daily practice in a Smoking Cessation Service. METHODS: This is a retrospective cohort study. It was carried on at a smoking cessation clinic in Madrid and used a convenience sampling strategy. We reviewed medical records of patients diagnosed with psychiatric disorders who attended a Smoking Cessation Service...
December 21, 2017: Revista Portuguesa de Pneumologia
keyword
keyword
77072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"